サイクリン依存性キナーゼ阻害薬の世界市場:パイプラインインサイト2021

【英語タイトル】Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2021

DelveInsightが出版した調査資料(DELV21SE026)・商品コード:DELV21SE026
・発行会社(調査会社):DelveInsight
・発行日:2021年9月
・ページ数:150
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:世界
・産業分野:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Global Site LicenseUSD7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

DelveInsight’s, “Cyclin-dependent-kinase-inhibitors – Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Cyclin-dependent-kinase-inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Cyclin-dependent-kinase-inhibitors Understanding
Cyclin-dependent-kinase-inhibitors: Overview
Cyclin-dependent kinases (CDKs) are a family of enzymes-serine threonine kinases – that, under normal physiological conditions, play significant roles in controlling cell-cycle progression and transcription regulation. Overexpression of some CDKs and their associated cyclins, as well as downregulation of CDK inhibitors (CKIs), can lead to abnormal cellular proliferation and cancer progression. Due to such dysregulation of CDKs in many cancers, targeting of this family of enzymes has emerged as a promising strategy in the treatment of multiple cancer types, including blood and solid tumours. Targeting the cell cycle via the CDK4/6-Rb axis has proven the most successful approach in the clinic to date. The FDA has approved the CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib as treatments for hormone receptor-positive (HR+) metastatic breast cancer (mBC), in combination with endocrine therapy.

“”Cyclin-dependent-kinase-inhibitors – Pipeline Insight, 2021″” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cyclin-dependent-kinase-inhibitors pipeline landscape is provided which includes the disease overview and Cyclin-dependent-kinase-inhibitors treatment guidelines. The assessment part of the report embraces, in depth Cyclin-dependent-kinase-inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cyclin-dependent-kinase-inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Cyclin-dependent-kinase-inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Cyclin-dependent-kinase-inhibitors.
Cyclin-dependent-kinase-inhibitors Emerging Drugs Chapters
This segment of the Cyclin-dependent-kinase-inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cyclin-dependent-kinase-inhibitors Emerging Drugs
• SHR6390: Jiangsu Hengrui Medicine Co.
SHR-6390 acts as inhibitors of Cyclin-dependent kinase 4 and Cyclin-dependent kinase 6. It is being developed by Jiangsu Hengrui Medicine for the treatment of Breast cancer.
• GB491 (lerociclib): Genor Pharma
GB491 (lerociclib) is a potent, selective, potentially best-in-class oral CDK4/6 for HR+/HER2-breast cancer in China. GB491 has consistently demonstrated efficacy in several pre-clinical models and clinical trials in HR+/HER2-breast cancer. CDK4/6 inhibitors in combination with fulvestrant represent an established treatment for HR+/HER2- advanced or metastatic breast cancer and have demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS). Preliminary results of clinical trials indicate that GB491 has a differentiated PK and tolerability profile from other CDK4/6 inhibitors, allowing for continuous dosing with fewer dose-limiting toxicities such as neutropenia and less complete blood count monitoring. Lerociclib is currently undergoing a Phase IIa clinical trial conducted by licensing partner, G1 Therapeutics.
Further product details are provided in the report……..

Cyclin-dependent-kinase-inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Cyclin-dependent-kinase-inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Cyclin-dependent-kinase-inhibitors
There are approx. 40+ key companies which are developing the therapies for Cyclin-dependent-kinase-inhibitors. The companies which have their Cyclin-dependent-kinase-inhibitors drug candidates in the most advanced stage, i.e. Pre-registration include, Jiangsu Hengrui Medicine Co.
• Phases
DelveInsight’s report covers around 40+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cyclin-dependent-kinase-inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cyclin-dependent-kinase-inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cyclin-dependent-kinase-inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-dependent-kinase-inhibitors drugs.

Cyclin-dependent-kinase-inhibitors Report Insights
• Cyclin-dependent-kinase-inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Cyclin-dependent-kinase-inhibitors Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Cyclin-dependent-kinase-inhibitors drugs?
• How many Cyclin-dependent-kinase-inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cyclin-dependent-kinase-inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cyclin-dependent-kinase-inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cyclin-dependent-kinase-inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Syros Pharmaceuticals
• Jiangsu Hengrui Medicine
• Aucentra Therapeutics
• Nuvation Bio
• MEI Pharma
• Vincerx Pharma
• Chordia Therapeutics
• Genor Pharma

Key Products
• SY-5609
• SHR-6390
• Auceliciclib
• AU2-94
• AU14-5
• AU2-85
• AU4-53
• NUV-422
• Voruciclib
• VIP-152
• CRD-1835439
• GB491

❖ レポートの目次 ❖

Introduction
Executive Summary
Cyclin-dependent-kinase-inhibitors: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
GB491: Genor Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
Voruciclib: MEI Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
AU2-94: Aucentra Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Cyclin-dependent-kinase-inhibitors Key Companies
Cyclin-dependent-kinase-inhibitors Key Products
Cyclin-dependent-kinase-inhibitors- Unmet Needs
Cyclin-dependent-kinase-inhibitors- Market Drivers and Barriers
Appendix



★調査レポート[サイクリン依存性キナーゼ阻害薬の世界市場:パイプラインインサイト2021] (コード:DELV21SE026)販売に関する免責事項を必ずご確認ください。
★調査レポート[サイクリン依存性キナーゼ阻害薬の世界市場:パイプラインインサイト2021]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆